Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about ...

This page features the latest news about the Checkpoint Therapeutics stock. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Checkpoint, Sonder ...

J ames F. Oliviero III, the CEO, President, and Director of Checkpoint Therapeutics , Inc. (NASDAQ:CKPT), recently sold shares worth $64,027 in two separate transactions.The company, currently ...

W illiam Garrett Gray, the Chief Financial Officer of Checkpoint Therapeutics , Inc. (NASDAQ:CKPT), recently sold 74,110 shares of the company’s common stock.The shares were sold at a weighted ...

Checkpoint Therapeutics Stock Performance NASDAQ:CKPT opened at $3.31 on Monday. The firm has a market capitalization of $161.63 million, a price-to-earnings ratio of -1.80 and a beta of 1.36 ...

On Tuesday, H.C. Wainwright maintained its Buy rating and $34.00 stock price target for Checkpoint Therapeutics (NASDAQ:CKPT). This affirmation follows Checkpoint Therapeutics' ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.